Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis;Okuläre Beteiligung bei Stevens-Johnson-Syndrom undToxisch epidermaler Nekrolyse

Klinische Monatsblatter fur Augenheilkunde

Volumn 229, Issue 5, 2012, Pages 534-539

  Chronopoulos, A ^a   Pleyer, U ^a   Mockenhaupt, M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

conjunctiva; cornea; ocular manifestation; pathology; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

ANTIINFLAMMATORY AGENT; LUBRICATING AGENT;

ARTICLE; BLINDNESS; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; EYE DISEASE; HUMAN; QUALITY OF LIFE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; EPIDERMAL NECROLYSIS, TOXIC; EYE INFECTIONS; HUMANS; STEVENS-JOHNSON SYNDROME;

EID: 84861005919     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0031-1299530     Document Type: Article

References (41)

1. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol: 1993; 129 92 96 (Pubitemid 23029676)
2. Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol: 2002; 138 1019 1024 (Pubitemid 34875605)
3. Rzany B, Hering O, Mockenhaupt M et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol: 1996; 135 6 11 (Pubitemid 26225106)
4. Rzany B, Mockenhaupt M, Baur S et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol: 1996; 49 769 773 (Pubitemid 26280728)
5. Mockenhaupt M, Liß Y. Schwere arzneimittelinduzierte Hautreaktionen: Stevens-Johnson-Syndrom und Toxisch epidermale Nekrolyse. Allergo J: 2011; 4 200 210
6. Edward J, Holland DRH. Ocular Infection and Immunity. [by Jay S. Pepose, Gary N. Holland and Kirk R.] St. Louis: Mosby Wilhelmus: 1996
7. Chang YS, Huang FC, Tseng SH et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea: 2007; 26 123 129
8. Power WJ, Ghoraishi M, Merayo-Lloves J et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology: 1995; 102 1669 1676
9. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol: 2008; 128 35 44 (Pubitemid 350249390)
10. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol: 2011; 7 803 813; quiz 814 - 805
11. Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med: 2008; 14(12) 1343 1350
12. Roujeau JC, Huynh TN, Bracq C et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol: 1987; 123 1171 1173 (Pubitemid 17119310)
13. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J: 2006; 6 265 268 (Pubitemid 44137953)
14. Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics: 2008; 18 99 107
15. Kauppinen K. Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulphonamides. Acta Derm Venereol Suppl (Stockh): 1972; 68 1 89
16. Foster CS, Fong LP, Azar D et al. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology: 1988; 95 453 462
17. Tugal-Tutkun I, Akova YA, Foster CS. Penetrating keratoplasty in cicatrizing conjunctival diseases. Ophthalmology: 1995; 102 576 585
18. Sotozono C, Ang LP, Koizumi N et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology: 2007; 114 1294 1302 (Pubitemid 47001496)
19. Thiel HJ, Richter U, Pleyer U et al. [Drug-induced exudative erythema multiforme major with a chronic progressive course and bilateral blindness. Clinical and immunohistologic follow-up]. Klin Monbl Augenheilkd: 1990; 197 142 149 (Pubitemid 20247030)
20. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol: 2007; 91 1048 1053 (Pubitemid 47122111)
21. Kuper K, Pleyer U, Zierhut M et al. [Erythema exsudativum multiforme major]. Ophthalmologe: 1995; 92 823 828
22. Mukasa Y, Craven N. Management of toxic epidermal necrolysis and related syndromes. Postgrad Med J: 2008; 84 60 65 (Pubitemid 351427571)
23. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm: 2002; 53 263 280 (Pubitemid 34303289)
24. Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface diseases. Arq Bras Oftalmol: 2008; 71 47 54
25. Schneck J, Fagot JP, Sekula P et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol: 2008; 58 33 40 (Pubitemid 350298143)
26. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science: 1998; 282 490 493 (Pubitemid 28483679)
27. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs: 2005; 65 2085 2090 (Pubitemid 41475790)
28. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol: 2003; 139 33 36 (Pubitemid 36091571)
29. Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol: 2000; 115 149 153 (Pubitemid 30637181)
30. Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet: 1998; 352 1586 1589 (Pubitemid 28515243)
31. Struck MF, Hilbert P, Mockenhaupt M et al. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med 36 22 32
32. Roujeau JC, Chosidow O, Saiag P et al. Toxic epidermal necrolysis (Lyell's syndrome). J Am Acad Dermatol: 1990; 23 1039 1058
33. Koizumi N, Inatomi T, Suzuki T et al. Cultivated corneal epithelial stem cell transplantation in ocular surface disorders. Ophthalmology: 2001; 108 1569 1574 (Pubitemid 32808330)
34. Giasson CJ, Bouchard C, Boisjoly H et al. [Amnion and ocular surface problems]. Med Sci (Paris): 2006; 22 639 644
35. Shay E, Kheirkhah A, Liang L et al. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol: 2009; 54 686 696
36. Dua HS, Azuara-Blanco A. Allo-limbal transplantation in patients with limbal stem cell deficiency. Br J Ophthalmol: 1999; 83 414 419 (Pubitemid 29161181)
37. Liu J, Sheha H, Fu Y et al. Oral mucosal graft with amniotic membrane transplantation for total limbal stem cell deficiency. Am J Ophthalmol 152 739 747 e731
38. Romero-Rangel T, Stavrou P, Cotter J et al. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol: 2000; 130 25 32
39. Gungor I, Schor K, Rosenthal P et al. The Boston Scleral Lens in the treatment of pediatric patients. J AAPOS: 2008; 12 263 267
40. Tougeron-Brousseau B, Delcampe A, Gueudry J et al. Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol: 2009; 148 852 859 e852
41. Liu C, Okera S, Tandon R et al. Visual rehabilitation in end-stage inflammatory ocular surface disease with the osteo-odonto-keratoprosthesis: results from the UK. Br J Ophthalmol: 2008; 92 1211 1217